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Received May 11, 2012; accepted July 26, 2012AbstractAscites formation in patients with cirrhosis, portal hypertension, or both usually results from hyperdynamic circulatory dysfunction, where
the retention of sodium and water is associated with the activation of the sympathetic and renineangiotensinealdosterone systems. The presence
of ascites indicates the development of liver decompensation. Furthermore, complications seen in conjunction with ascites such as spontaneous
bacterial peritonitis, hepatorenal syndrome, and hepatic hydrothorax may result in increased morbidity and mortality. Although non-
pharmacological, pharmacological, and surgical approaches have been introduced and clinically practiced, their therapeutic effects are still
suboptimal or limited by their potential side effects, such as large-volume paracentesis-induced postparacentesis circulatory dysfunction. Herein,
we discuss strategies to prevent and properly manage ascites-related complications, including a review of the literature and controlled studies
that assess these strategies.
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Ascites formation is defined as a condition of abnormal
accumulation of fluid in the abdomen. Liver cirrhosis is the
most common among the medical and surgical conditions
associated with ascites formation, and is responsible for 81%
of cases.1 In fact, ascites is actually the most common
complication of liver cirrhosis.2 Approximately 10% of
patients with cirrhosis have ascites, and 50e70% of newly
diagnosed patients with cirrhosis develop ascites within 10
years. The presence of ascites is regarded as a turning point in
such patients, because it suggests the development of liver
decompensation. An elevated risk of mortality has been noted
among patients with ascites, with an increasing rate of 15% in
the 1st year and 44% in the 5 years3 after its diagnosis. As* Corresponding author. Dr. Hui-Chun Huang, Division of Gastroenterology,
Department of Medicine, Taipei Veterans General Hospital, 201, Section 2,
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http://dx.doi.org/10.1016/j.jcma.2012.11.005cirrhosis progresses, ascites becomes refractory to diuretic
control, where the survival rate of the patient 1 year after
diagnosis is further reduced to only 50%. Therefore, the
presence of refractory ascites is generally considered to be an
adverse prognostic indicator.
Because the efficacy of currently available treatments is
still unsatisfactory, much effort has been spent searching
a better treatment strategy. This review aims to discuss the
pathophysiology, pharmacological treatment options, and their
impacts on large-volume paracentesis (LVP)-induced post-
paracentesis circulatory dysfunction (PCD) in decompensated
cirrhotic patients with ascites, partly based on the relevant
existing literature.
2. Pathophysiology
The pathophysiology of ascites formation is depicted in
Fig. 1. Typically, cirrhosis of the liver increases intrahepatic
resistance by the disruption of intrahepatic blood flow through
several mechanisms: first, by sinusoidal fibrosis andhinese Medical Association. All rights reserved.
Fig. 1. The pathophysiology of ascites formation in cirrhosis.
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exaggerated intrahepatic vasoconstriction (functional compo-
nent). Meanwhile, the enhanced release of splanchnic vaso-
dilatory substances, particularly nitric oxide,4,5 induces
splanchnic hyperemia and increases portal inflow. Taken
together, increased hepatic resistance accompanied by hyper-
dynamic splanchnic circulation results in significantly elevated
portal pressure, customarily presenting as portal hypertension.
Hyperdynamic circulation in cirrhosis and/or portal
hypertension6 is characterized by circulatory dysfunction
including decreased total peripheral vascular resistance,
increased heart rate and cardiac output. The initial event in this
process is believed to be peripheral vasodilatation. Conse-
quently, the redistribution of blood flow leads to reduced vital
organ perfusion, further causing effective hypovolemia. Along
with arterial hypotension, they activate the volume- and
baroreceptor-mediated sympathetic system, leading to
increased cardiac output and vasoconstriction. Furthermore,
the renineangiotensinealdosterone (RAA) system is activated
to compensate for the effective hypovolemia, with the primary
result being retention of renal sodium and water.
Influenced by elevated intrasinusoidal pressure due to liver
cirrhosis and increased intravascular volume due to renal
hyponatriuresis, hydraulic pressure over the capillary net of
portal system gradually increases, which forces the fluid
moving across the hepatic capsule into the peritoneum. The
process is evidenced by the high serum-ascites albumin
gradient in patients with cirrhotic ascites (1.1 g/dL), which
implies abnormally high intravascular pressure.
3. Management of ascites
The control of ascites should be undertaken whenever it
becomes necessary to relieve abdominal discomfort, alleviate
shortness of breath, improve appetite, prevent spontaneousbacterial peritonitis (SBP),7 or reduce the risk of abdominal
wall hernia. In brief, the main goal is to improve the quality of
life with the prerequisite of maintaining a stable hemodynamic
condition.
In the early stage, ascites can be controlled by just
restricting dietary salt intake. However, as the disease prog-
resses, the excretion of urinary sodium gradually decreases,
and diuretics must be used to promote efficient urinary sodium
excretion. Unfortunately, even with diuretic use, the amount of
urinary sodium excreted could be <10 mmol/day in patients
with advanced liver cirrhosis. Eventually, it is customary to
find supervening ascites refractory to pharmacological
treatment.
4. Control of refractory ascites4.1. DefinitionRefractory ascites are defined by the International Ascites
Club as “ascites that cannot be mobilized, or early recurrence
of which cannot be satisfactorily prevented by medical
therapy.”8 In the largest randomized controlled trial performed
in patients with ascites due to liver cirrhosis caused by alco-
holism, it was found that more than 90% of ascites could be
controlled by a combination of diet modification and treatment
with diuretics.9 This result suggests that approximately 10% of
ascites are resistant to treatment with diuretics.4.2. LVPIt has been observed that LVP removes ascites in a short
time and quickly relieves tense ascites. LVP is effective and
safe, and thus it has become a routine procedure in clinical
practice.10 However, LVP obviously does not correct the
underlying condition of ascites. As a result, LVP is regarded as
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a definitive treatment choice. It is worth noting that the rapid
removal of a large volume of ascites inevitably results in the
activation of the RAA system, which will be discussed in the
following section.4.3. Transjugular intrahepatic portosystemic shuntTransjugular intrahepatic portosystemic shunt (TIPS) is an
intrahepatic portosystemic shunt that bypasses the blood flow
from the portal venous branch to the hepatic venous branch. It
relieves portal hypertension and thus alleviates ascites
formation. Results of various studies involving meta-analyses
show that TIPS provides better ascites control than serial
LVP.11e13 However, encephalopathy is a concern because the
bypassed blood containing neurotoxins, including ammonia,
cannot be appropriately processed by the liver. Many studies
have been carried out to survey patient selection criteria,
trying to improve diagnostic and treatment efficacy and also to
reduce the complications of this procedure.4.4. PharmacotherapyPeripheral vasodilatation, activation of the sympathetic
system, hyperarousal of the RAA system, and retention of
sodium are the main causes of ascites formation. However, the
use of novel pharmacologic agents counteracting these effects,
including albumin, terlipressin, satavaptan, midodrine, and
nonselective b-blocker (NSBB) have been investigated in the
past few years (Table 1).4.5. AlbuminAlbumin is a 66-kDa protein that constitutes 50e60% of
serum protein. The main physiological function of albumin is
to retain ongoing intravascular osmotic pressure and to
maintain effective circulating volume. As a colloid volumeTable 1
Summary of recent advances in the pharmacological treatment of cirrhotic patient
Agent References Aim
Albumin Bernardi et al19 The role of albumin (6e8 g/L of ascites
removal) as adjuvant therapy in LVP
Albumin Alessandria et al25 The effect of half-dose (4 g/L of ascites
removal) of albumin as adjuvant therapy i
LVP
Terlipressin Fimiani et al30 The role of terlipressin in short-term (3 wee
refractory ascites control
Satavaptan Wong et al35 The role of satavaptan in long-term (52 wee
refractory ascites control
Midodrine Singh et al38 The role of midodrine in long-term (12
months) refractory ascites control
Propranolol Serste´ et al43 The impact of propranolol on cirrhotic pat
with refractory ascites
LVP ¼ large-volume paracentesis.
a Level A ¼ data derived from randomized clinical trials or meta-analyses; leve
level C ¼ only consensus opinion of experts, case studies, or standard of care.expander, albumin has been used to “fill” potentially inade-
quate intravascular volume, especially after LVP.
Removing a large amount of ascites in a short period may
induce circulatory dysfunction because of the sudden reduc-
tion of effective circulating volume with reactivation of RAA
and sympathetic systems, a condition known as PCD (usually
defined as an elevation of renin level up to 50% from base-
line). Existing evidence indicates that PCD was associated
with acute reaccumulation of ascites, hepatorenal syndrome
(HRS), and dilutional hyponatremia.14,15 One study even
found that PCD increased the risk of patient mortality.16
Until now, the most effective method to prevent LVP-
related circulatory dysfunction was the adjuvant administra-
tion of albumin.17 In the European Association for the Study
of the Liver (EASL) practice guidelines, it is suggested that
cases with LVP greater than 5 L of ascites should involve
albumin administration. However, this recommendation is
only based on a consensus of expert opinions, notwithstanding
the fact that the current available data remain controversial.
Furthermore, questions over the effectiveness of any other
volume expander, when compared with albumin, exist. A
systematic review in 2008 concluded that, regarding morbidity
and mortality, there was no evidence that albumin is superior
to other volume expanders as an adjunctive therapy to LVP.18
In 2011, Bernardi et al reported a meta-analysis comparing
the effectiveness of albumin with other volume expanders
(dextran, gelatin, hydroxyethyl starch, and hypertonic saline)
and vasoconstrictors (terlipressin, epinephrine, and mido-
drine).19 They concluded that adjuvant administration of
albumin while performing LVP for patients with tense ascites
reduces mortality and morbidity rates compared with other
agents. However, because the co-administration of albumin
and vasoconstrictors had not been introduced until this
century, most available data were from pilot studies,20e24 and
therefore, further studies are needed to clarify this issue.
It is worth noting that although EASL guidelines recom-
mended albumin as a plasma expander during LVP, the
appropriate dose has not been thoroughly surveyed. The EASLs with refractory ascites.
Note Level of
evidencea
Impact on survival
Meta-analysis A Possibly positive
n
Randomized control pilot study B Not applicable
ks) Multicentric, prospective study B Not applicable
ks) Randomized control study A Negative
Randomized control pilot study B Positive
ient Cross-over study C Not applicable
l B ¼ data derived from a randomized pilot study, or nonrandomized studies;
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ascitic fluid removed, while the American Association for the
Study of Liver Diseases guidelines suggest 6e8 g/L of ascites
removed. In 2011, Alessandria et al proposed a prospective,
randomized unblended pilot study to compare standard versus
half doses of albumin.25 A total of 70 patients treated with
LVP were randomized to receive albumin, with one group (35
patients) receiving 4 g of albumin for every liter of ascites
removed and another group (35 patients) receiving 8 g of
albumin for every liter of ascites removed. The authors found
that there was no significant difference in the incidence of
PCD, hyponatremia, or renal failure between the two groups.
The 6-month survival rates of both groups were also the same.
In conclusion, adjuvant administration of albumin during
LVP significantly reduces the incidence of PCD, which is an
important risk factor for reaccumulation of ascites and renal
failure. Administration of albumin is also beneficial in
reducing PCD among colloid agents. Regarding mortality,
however, further studies are still required to identify the effi-
cacy of albumin.4.6. TerlipressinTerlipressin, an extended-acting vasopressin derivative,
elicits splanchnic vasoconstriction by selectively binding
vasopressin type 1 receptors located in the smooth muscle
cells of the splanchnic vessels. Through redistributing the
blood flow of the splanchnic vasculature and the portosystemic
collateral vascular bed,26 terlipressin effectively increases the
renal blood flow and is considered to be the standard therapy
for HRS.27
In recent years, the therapeutic role of terlipressin in
cirrhotic patients with refractory ascites has started to draw
attention because of its ability to improve renal perfusion. A
single dose of terlipressin significantly increases the excretion
of sodium and decreases the activity of plasma renin in
patients with cirrhosis.28,29 A randomized control study further
demonstrated that terlipressin prevents LVP-induced PCD.22
In 2011, a multicenter study aiming to evaluate the effect of
terlipressin on refractory ascites was reported.30 The study
included 26 cirrhotic patients with refractory ascites that were
controlled by a combination of albumin and diuretics. The
result suggested that the combination of terlipressin and
albumin controlled ascites better than the combination of
diuretics and albumin.
To sum up, terlipressin may have the potential to improve
renal sodium excretion by enhancing renal perfusion and thus
contributing to improved ascites control. However, further
studies are needed to determine the role of terlipressin in
adjuvant therapy of LVP.4.7. SatavaptanVaptans selectively antagonize the vasopressin type 2
receptors on principal cells, inhibiting the reabsorption of free
water and increasing the concentration of serum sodium. It
was first developed for the treatment of syndrome ofinappropriate antidiuretic hormone (SIADH) secretion.31
Currently, vaptans are approved for the management of
hyponatremia in patients with cirrhosis and ascites,32 heart
failure, and SIADH. During the treatment of hyponatremia in
patients with edema, vaptans were found to diminish the
severity of ascites.33 Short-term phase II studies using sata-
vaptan in cirrhotic patients with ascites also showed a decrease
in ascites volume.34
In 2012, Wong et al reported the results of three random-
ized, double-blind studies with a total of 1200 enrolled
patients.35 In cirrhotic patients with ascites, satavaptan could
not prevent the deterioration of ascites during 48 weeks of
follow-up. Furthermore, in patients who received LVP, sata-
vaptan increased mortality ( p ¼ 0.049). In conclusion,
although satavaptan corrected hyponatremia in patients with
cirrhosis, it lacks a therapeutic effect for ascites control.
Meanwhile, the long-term safety and efficacy of vaptans in the
management of hyponatremia in patients with cirrhosis merits
further investigation.4.8. MidodrineMidodrine hydrochloride, an oral a1-agonist, has been
approved by the US Food and Drug Administration to treat
symptomatic orthostatic hypotension. It is a prodrug that is
absorbed from the gastrointestinal tract and is metabolized by
the liver into an active metabolite, desglymidodrine.36 It
increases effective circulating blood volume and renal
perfusion by increasing systemic and splanchnic blood
pressure.
Although peripheral vasodilatation has been regarded as the
main factor that induces hyperdynamic circulation and sodium
retention in patients with cirrhosis, the therapeutic role of
arteriole vasoconstrictor remained controversial until the late
1990s. In 1998, Angeli et al reported the acute effect of
midodrine on 25 nonazotemic cirrhotic patients with ascites.37
Midodrine, 6 hours after administration, effectively improved
systemic hemodynamics, renal perfusion, and urine sodium
excretion. The activity of the RAA system was also
suppressed.
In 2012, Singh et al reported a pilot randomized study
evaluating the effect of long-term midodrine administration on
ascites control.38 The study included 40 patients with cirrhosis
and refractory or recurrent ascites. The result showed that
administration of midodrine combined with standard therapy
for 3 months significantly controlled ascites when compared
with placebo. In addition, significantly decreased cardiac
output and plasma renin activity were also observed during the
study period. Moreover, the survival rate was significantly
improved in the midodrine group ( p < 0.046).
In conclusion, although the available data are still not
sufficiently proven to support the proposition that midodrine
can be efficacious in ascites control, the results from pilot
studies are encouraging. They highlight an alternative way to
ameliorate decompensated liver cirrhosis and ascites by alle-
viating hyperdynamic circulation, which is different from
RAA or sympathetic system control.
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control portal pressure. In 1981, Lebrec et al found that
propranolol effectively prevented recurrent esophageal varices
bleeding in patients with cirrhosis.39 Following that encour-
aging revelation, the roles of NSBBs were extensively evalu-
ated. NSBBs, including propranolol and nadolol, are now
considered to be the most effective portal hypotensive agents
by inhibiting splanchnic vasodilatation and reducing portal
inflow and portal pressure. Patients undergoing NSBBs treat-
ment with a concomitant reduction of hepatic venous pressure
gradient (HVPG) >20% of baseline or <12 mmHg have
reduced risk of variceal bleeding and had an improved survival
rate.40,41 In addition, NSBBs responders had a lower risk of
portal hypertension-related complications, including ascites,
SBP, HRS, and hepatic encephalopathy.42
In 2010, Lebrec and his colleagues reported that the use of
NSBBs may be associated with poor survival rates in cirrhotic
patients with refractory ascites.43 However, the study had
some limitations,44 including the fact that Lebrec’s investi-
gation was not a randomized control trial. Nevertheless, the
study still raised an important concern about the safety of
propranolol use in cirrhotic patients with refractory ascites.
Based on these results, in 2011, the same research team con-
ducted a self-controlled cross-over study to evaluate the rela-
tionship between b-blockers and PCD.45 The study included
10 cirrhotic patients with refractory ascites undergoing NSBBs
treatment. PCD developed in eight patients during propranolol
treatment, even when albumin was administered after LVP.
However, once the use of propranolol was discontinued, PCD
developed in only one patient after LVP. Although the number
of cases analyzed was relatively small, the findings could
suggest that NSBBs induced more PCD in patients with
cirrhosis and refractory ascites managed by LVP.
Although these two studies provoked a debate on the safety
of using NSBB in advanced cirrhotic patients with refractory
ascites, in patients with compensated cirrhosis and large
varices treated with b-blockers, an HVPG decrease 10%
significantly reduced the risk of developing ascitic decom-
pensation and other related complications such as refractory
ascites or HRS.46 Therefore, the risk and benefit of NSBBs
may vary according to the severity of cirrhosis, and further
studies are warranted to identify the impact of NSBBs on
patients with refractory ascites.
5. Complications of ascites5.1. SBPSBP is diagnosed by a positive ascitic fluid bacterial culture
with an absolute ascitic polymorphonuclear neutrophil count
>250 cells/mm3. It develops in 30% of patients with ascites,
and even with adequate treatment, the mortality rate is still as
high as 20%. As a result, SBP prophylaxis is an important
issue in the management of ascites. Because long-term anti-
biotic prophylaxis inevitably induces resistant bacterial strain,only patients at high risk for SBP are supposed to benefit from
prophylaxis.5.2. Primary prophylaxis of SBPThe strategy of primary prophylaxis is prophylactic appli-
cation of antibiotics to decrease the incidence of SBP in high-
risk patients who never had SBP. Cirrhotic patients with acute
gastrointestinal bleeding are at a high risk of developing SBP,
and prophylactic antibiotics should routinely be prescribed. In
the patients with cirrhosis, oral administration of 400 mg of
norfloxacin two times per day for 7 days had been proven to
prevent SBP.47 For those patients with active bleeding that
precludes enteral feeding, intravenous administration of
400 mg ofloxacin per day is an alternative.48 Because of the
emergence of quinolone-resistant bacteria, a recent study
conducted in Spain showed that intravenous administration of
ceftriaxone was superior to oral norfloxacin in patients with
acute gastrointestinal bleeding and advanced liver cirrhosis.49
Therefore, it may be crucial for clinicians to prescribe
prophylactic antibiotics according to regional bacterial
epidemiology.
Long-term primary prophylaxis is strongly recommended
for cirrhotic patients with ascites fluid protein <1.5 g/dL and
suffering from either (1) serum creatinine levels greater than
1.2 mg/dL; (2) blood urea nitrogen levels greater than 25 mg/
dL; (3) serum sodium levels less than 130 mEq/L; or (4)
ChildePugh class C score with bilirubin levels greater than
3 mg/dL. In these conditions, administration of norfloxacin or
trimethoprim/sulfamethoxazole is appropriate. Compared with
daily dosing, a single oral weekly dose of ciprofloxacin was
also effective in preventing SBP. However, intermittent dosing
was later proven to select resistant flora more rapidly.505.3. Secondary prophylaxis of SBPIn patients who have experienced SBP, the recurrence rate
is as high as 70%. However, secondary prophylaxis with
norfloxacin dramatically reduced the recurrence rate from
68% to 20%.51 Other antibiotics such as ciprofloxacin or
trimethoprim/sulfamethoxazole are also effective in the
prevention of SBP.52 The secondary prophylaxis should be
continued indefinitely until the ascites are resolved or liver
transplantation can be performed.5.4. Treatment of SBPOnce a patient is diagnosed to have SBP, empirical anti-
biotics should be given as soon as possible. Most pathogens of
SBP are Gram-negative bacteria translocating from the gut,
such as Escherichia coli, Klebsiella pneumonia, and Strepto-
coccus pneumoniae. Consequently, a third-generation cepha-
losporin is a reasonable choice. Amoxycillin/clavulanic acid
and quinolones are alternative choices. However, using the
same category of antibiotics both in acute treatment and in
prophylaxis should be avoided because of the rapid selection
of resistant strains.53 In selective patients, antibiotics
128 S.-J. Hsu, H.-C. Huang / Journal of the Chinese Medical Association 76 (2013) 123e130treatment for 5 days is enough. Follow-up paracentesis may
not be mandatory because most SBP resolved after
treatment.546. HRS6.1. Prophylaxis of HRSHRS is a unique form of acute renal failure that only occurs
in advanced liver disease, which results from hemodynamic
changes and subsequently hypoperfusion of the kidney. Type 1
HRS is characterized by rapidly progressive renal failure, with
a doubling of serum creatinine to a level greater than 2.5 mg/
dL or a deterioration of creatinine clearance to less than
20 mL/minute over a period of less than 2 weeks. The prog-
nosis of individuals with type 1 HRS is poor, with a mortality
rate exceeding 50% after 1 month.55 In contrast, type 2 HRS is
slower in onset and milder in progression.
Until now, only albumin infusion has proven to be effective
in the prophylaxis of HRS in patients with SBP.56 Besides
volume expansion, albumin also plays a role in removing
cytokines and bacterial products. This is why albumin is
superior to other volume expanders in the prevention of HRS.6.2. Treatment of HRSThe use of vasoconstrictive agents in combination with
albumin is currently the most effective pharmaceutical therapy
for HRS. However, the use of terlipressin, norepinephrine, or
midodrine plus octreotide has been studied as well.57 Among
them, coadministration of terlipressin and albumin signifi-
cantly improves renal function and should be considered as the
first-line therapy.58 Nevertheless, there is still no definite
evidence to support the proposition of an enhanced survival
benefit from the regimen. Until now, only liver transplantation
improves the survival of patients with HRS.597. Hepatic hydrothorax
Hepatic hydrothorax indicates a pleural effusion >500 mL
in cirrhotic patients without cardiopulmonary disease. It
develops in approximately 5% of cirrhotic patients with ascites
and is usually right sided, which accounts for 85% of the
cases. Hepatic hydrothorax can present without clinically
detectable ascites. Nevertheless, compared with those with
ascites, those without ascites have larger diaphragmatic
defects.60 The pleural fluid is derived from the pathological
transdiaphragmatic migration of ascites, and the defects are
usually the ruptured pleuroperitoneal blebs. Because of
negative intrathoracic pressure during breathing, there is
a unidirectional flow of ascitic fluid to the pleural space. The
peritonealepleural communication can be revealed by
a nuclear medicine scan with radiolabeled albumin or 99mTc-
sulfur colloid or thoracoscopy.7.1. Treatment strategiesThe medical treatment modalities include sodium and fluid
restriction, diuretics, abdominal paracentesis, intermittent or
pig-tail drainage of pleural fluid, chemical pleurodesis with or
without continuous positive airway pressure (CPAP), and
TIPS. Approximately 10% of those patients not responding to
sodium restriction and maximal tolerable doses of diuretics are
considered to have refractory hydrothorax, and in such cases
alternative treatment options must be considered. It is worth
noting that insertion of a chest tube is not recommended, due
to severe complications such as massive fluid shifts, protein
and electrolyte depletion, and acute renal damage.61 The effect
of chemical pleurodesis, in contrast, is suboptimal as the fluid
is formed very rapidly and allows the visceral and parietal
pleural surfaces to approximate and adhere. As a result,
incomplete adhesions may be formed, which results in locu-
lated pleural effusions. Under such circumstances, CPAP
appears to be helpful in decreasing negative pleural pressure
and thus preventing the shift of fluid from the peritoneal to the
pleural space. In addition, it has been shown that TIPS is
another treatment option. In a recent study with 73 enrolled
patients, the rates of favorable clinical response within 1
month and at 6 months after TIPS were 79% and 75 %,
respectively, and the median survival duration was 517 days. A
model for end-stage liver disease score <15 and clinical
response were significantly and independently associated with
overall survival.62
In conclusion, the medical management of ascites by die-
tary sodium restriction and diuretics therapy has been widely
accepted and recommended. However, its therapeutic efficacy
is still suboptimal. With accumulating evidence addressing the
pathophysiology of ascites formation, several avenues that aim
to halt the vicious cycle of refractory ascites are under
development (Fig. 1). In the past few years, results from
investigations surveying some pharmacological agents have
been encouraging. In the meantime, caution should be exer-
cised when interpreting the data. Both the “encouraging signs”
and the “warning signs” presented in these investigations may
be of some use now, but they continue to highlight the need for
further large-scale and randomized studies.References
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